A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients.

@article{Wang2019ARM,
  title={A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients.},
  author={T. Wang and B. Wu and X. Hu and Jin-ping Liu and T. Zhang and F. Li and B. Sun and L. Cai and Xinzheng Li and Zhiyue Chen and Q. Yang and Z. Jiang},
  journal={Annals of translational medicine},
  year={2019},
  volume={7 9},
  pages={
          196
        }
}
  • T. Wang, B. Wu, +9 authors Z. Jiang
  • Published 2019
  • Medicine
  • Annals of translational medicine
  • Background This study aimed to evaluate the efficacy and safety of mecapegfilgrastim (HHPG-19K) with different doses compared to granulocyte colony-stimulating growth factor (G-CSF) in treating chemotherapy-induced neutropenia in breast cancer patients. Methods A total of 182 breast cancer patients were enrolled in this multi-center, randomized, phase II trial and developed neutropenia after first cycle chemotherapy. Patients were then assigned as 1:1:1 ratio to receive 100 µg/kg HHPG-19K… CONTINUE READING
    10 Citations
    Mecapegfilgrastim in Chemotherapy-Induced Neutropenia: A Profile of Its Use in China
    • 1
    • Highly Influenced
    Is PEGylated G-CSF superior to G-CSF in patients with breast cancer receiving chemotherapy? A systematic review and meta-analysis
    Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
    • 23
    • PDF

    References

    SHOWING 1-10 OF 24 REFERENCES
    First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
    • 428
    Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
    • 461
    • Highly Influential
    Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
    • J. Vose, M. Crump, +8 authors B. C. Liang
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2003
    • 164
    A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
    • M. Green, H. Koelbl, +11 authors M. Piccart
    • Medicine
    • Annals of oncology : official journal of the European Society for Medical Oncology
    • 2003
    • 507
    Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy
    • 33
    Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    • 30
    Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study
    • 48
    • Highly Influential